NCT06863584View on ClinicalTrials.gov

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 1, 2032

Conditions
Solitary Plasmacytoma
Interventions
DRUG

Lenalidomide (Revlimid)

10mg po for 21 days, followed by a 7-day rest period.

RADIATION

SBRT

PTV 30Gy/5f and/or PGTV 35Gy/5F.

Trial Locations (1)

Unknown

RECRUITING

2nd Affiliated Hospital, School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER